NEW YORK — Biolidics said on Tuesday that it has partnered with Japanese diagnostics firm Sysmex on the development of a liquid biopsy-based cancer test for the Asian market.
The companies have been collaborating since 2016 on a liquid biopsy system that combines Biolidics' ClearCell FX1 automated label-free circulating tumor cell separation and enrichment platform with Sysmex's MI-FCM molecular imaging flow cytometer system.